Integer Holdings ITGR Cardiac Rhythm Management & Neuromodulation — Total sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Integer Holdings in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Integer Holdings’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Integer Holdings's cardiac rhythm management & neuromodulation — total sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Integer Holdings's cardiac rhythm management & neuromodulation — total sales?
- Integer Holdings (ITGR) reported cardiac rhythm management & neuromodulation — total sales of $168.26M in Q1 2026.
- How has Integer Holdings's cardiac rhythm management & neuromodulation — total sales changed year-over-year?
- Integer Holdings's cardiac rhythm management & neuromodulation — total sales increased by 4.9% year-over-year, from $160.35M to $168.26M.
- What does cardiac rhythm management & neuromodulation — total sales mean?
- This metric represents the aggregate revenue generated from the Cardiac Rhythm Management and Neuromodulation product lines. It reflects the total market demand and commercial success of medical device components and finished systems designed for heart rhythm regulation and neurological therapy. Tracking this figure allows investors to assess the growth trajectory and market penetration of the company's specialized medical technology portfolio.